Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-β-Ala, a novel dermorphin analogue with high affinity at μ-opioid receptors

European Journal of Pharmacology

Volumn 395, Issue 2, 2000, Pages 107-112

  Sakurada, Shinobu ^a   Takeda, Satoshi ^a   Sato, Takumi ^a   Hayashi, Takafumi ^a   Yuki, Masayuki ^a   Kutsuwa, Motoharu ^a   Tan No, Koichi ^a   Sakurada, Chikai ^b   Kisara, Kensuke ^a   Sakurada, Tsukasa ^b  

^a Tohoku Pharmaceutical U ^*  (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

Author keywords

Funaltrexamine; 1 Opioid receptor; Dermorphin N terminal tetrapeptide; Naloxonazine; Tail flick test

Indexed keywords

BETA FUNALTREXAMINE; DERMORPHIN DERIVATIVE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MU OPIATE RECEPTOR; NALOXONAZINE; OPIATE ANTAGONIST; RECEPTOR SUBTYPE; TYROSYL DEXTRO ARGINYLPHENYLALANYL BETA ALANINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; MALE; MESODERM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; DRUG ANTAGONISM; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; OLIGOPEPTIDES; OPIOID PEPTIDES; PAIN MEASUREMENT; RECEPTORS, OPIOID, MU; TIME FACTORS;

EID: 0034724654     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00166-7     Document Type: Article

References (27)

1. Broccardo M., Erspamer V., Falconieri, Erspamer G., Importa G., Linari P., Melchiorri P., Montecucchi P.C. Pharmacological data on dermorphins, a new class of potent opiod peptides from amphibian skin. Br. J. Pharmacol. 73:1981;625-631.
2. Brown G.P., Yang K., King M.A., Rossi G.C., Leventhal L., Chang A., Pasternak G.W. 3-Methoxynaltrexone, a selective heroin/morphine-6β-glucuronide antagonist. FEBS Lett. 412:1997;35-38.
3. Chaki K., Sakurada S., Sakurada T., Kensuke K., Suzuki K. N-terminal tetrapeptide of dermorphin and D-Arg-substituted tetrapeptides: inactivation process of the antinociceptive activity by peptidase. Life Sci. 46:1990;1671-1678.
4. 2]-dermorphin tetrapeptide analogs and morphine in mice. Pharmacol. Biochem. Behav. 31:1988;439-444.
5. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
6. De Castiglione R., Rossi A.C. Structure-activity relationships of dermorphin synthetic analogues. Peptides (Fayetteville). 6:1985;117-125.
7. Elliott J., Smart D., Lambert D.G., Traynor J.R. Characterization of μ-opioid receptors on SH-SY5Y cells using naloxonazine and β-funaltrexamine. Eur. J. Pharmacol., Mol. Pharmacol. Sec. 268:1994;447-450.
8. Haley T.J., McComick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
9. Heyman J.S., Williams C.L., Burks T.F., Mosberg H.I., Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse; studies with naloxonazine. J. Pharmacol. Exp. Ther. 245:1988;238-243.
10. Hylden J.L.K., Wilcox G.L. Intrathecal morphine in mice:a new technique. Eur. J. Pharmacol. 67:1980;313-316.
11. Krumins S. Characterization of dermorphin bindings to membrances of rat brain and heart. Neuropeptides. 9:1987;93-102.
12. Ling G.S.F., Simantov R., Clark J.A., Pasternak G.W. Naloxonazine action in vivo. Eur. J. Pharmacol. 129:1986;33-38.
13. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
14. Matthes H.W.D., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptpms in mice lacking the mu-opioid-receptor gene. Nature. 383:1996;819-823.
15. Pasternak G.W. Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16:1993;1-18.
16. Paul D., Bodnar R.J., Gistrak M.A., Pasternak G.W. Different μ receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur. J. Pharmacol. 168:1989;307-314.
17. 2 opioid actions. Life Sci. 48:1991;2005-2011.
18. Recht L.D., Pasternak G.W. Effects of β-funaltrexamine on radiolabeled opioid binding. Eur. J. Pharmacol. 230:1987;341-344.
19. Rossi G.C., Leventhal L., Pan Y.-X., Cole J., Su W., Bondnar R.J., Pasternak G.W. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6β-glucronide antinociception. J. Pharmacol. Exp. Ther. 281:1997;109-114.
20. Sakurada S., Zadina J.E., Kastin A.B., Katsuyama S., Fujimura T., Murayama K., Yuki M., Ueda H., Sakurada T. Differential involvement of μ-opioid receptor subtypes in endomorphin-1- and 2-induced antinociception. Eur. J. Pharmacol. 372:1999;25-30.
21. Salvadori S., Sarto G., Tomatis R. Synthesis and Pharmacological activity of dermorphin and its N-terminal sequence. Int. J. Protein Res. 19:1982;536-542.
22. 2 and its fluorinated aromatic acid derivatives. Chem. Pharm. Bull. 39:1991;2316-2318.
23. 1-opioid receptors to morphine-induced antinociception. Eur. J. Pharmacol. 369:1999;183-187.
24. Schuller A.G.P., King M.A., Zhang J., Bolan E., Pan Y.-X., Morgan D.J., Chang A., Czick M.C., Unterwald E.M., Pasternak G.W., Pintar J.E. Retention of heroin and morphine-6β-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat. Neurosci. 2:1999;151-156.
25. Stevens C.G., Yaksh T.L. Spinal action of dermorphin, an extremely potent opioid peptide from frog skin. Brain Res. 385:1986;300-304.
26. Tallarida R.J., Murray R.B. Manual of Pharmacological Calculations with Computer Programs. 1987;Springer-Verlag, New York.
27. Zimprich A., Simon T., Hollt V. Cloning and expression of an isoform of the rat μ opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1. FEBS Lett. 359:1995;142-146.